anim health market remain well posit steadi annual growth zoeti
market leader revenu growth forecast high end industri rang
higher ep gain upsid possibl
ww anim health market estim grow annual ex fx
impact companion anim segment estim faster grow compound-annual-growth-rate
due influx new drug product anim segment estim grow
compound-annual-growth-rate driven on-going demand safe protein zoeti market
leader total industri sale well posit segment
result updat model increas revenu
reflect upsid sale also updat quarterli progress
better reflect expect neg impact account calendar chang
tough compar livestock revenu estim unchang
made modest adjust gpm spend line ep
estim unchang
given confid industri backdrop zoeti lead posit potenti
upsid top bottom line estim rais pt
ep ep
pleas see page report import disclosur
rate share outperform base rel attract anim health
market solid outlook top- bottom-lin growth versu market
upsid possibl believ execut prospect move share higher
despit standout perform
apoquel cytopoint sale trend
sale compound-annual-growth-rate
ep compound-annual-growth-rate
apoquel cytopoint simparica uptak
apoquel cytopoint simparica sale
greater expect
signific product emerg
new oper restructur
restructur provid greater
influx small new competitor dampen
zoeti inc engag discoveri develop manufactur commerci
anim health medicin vaccin focu livestock companion anim
primari livestock speci cattl beef dairi swine poultri sheep fish
primari companion anim speci dog cat hors zoeti spun
cowen compani
compani data cowen compani
compani data cowen compani
state livestock revenu livestock lc ex companion companion lc ex lc ex revenu contract ww lc ex total dog revenu cowen
compani data cowen compani
compani data cowen compani
compani data cowen compani
state livestock revenu livestock lc ex companion companion lc ex lc ex revenu contract ww lc ex total total dog cowen
compani data cowen compani
compani data cowen compani
compani data cowen compani
state livestock larg cattl also swine poultri sheep farm fish apoquel simparica new product drive growthtot ahead market growth revenu streamlin driven demand protein livestock lc ex pharmaq farm fish ad companion new product expand pet care companion lc ex -restructur lc ex revenu line market growth upsid possibl new product key apoquel cytopoint simparica contract tie former pfizer contractstot ww lc ex strong em demand safe protein beef dairi solid demand asia on-going steadi demand trend toward antibiotic-fre farm fish ad pharmaq sheep othertot speci trend vari geographicallycompanion total dog new product line extens drive growth nich markettot could even faster given potenti influx new drugscontract activ pursuedtot revenu steadi gain post restructur upsid possibl cowen
compani data cowen compani
ceftiofur rev market sinc draxxin rev market sinc anti-infect reflect sku reductionanti-infect exclud growth promot livestock companion anim product pharmaq farm fish vaccin ad revolut price/or competit mainli felin use nich dog simparica oral flea tick launch april eu parasiticid mostli livestock includ fishparasiticid boost pharmaq growth south amer em non-med import includ ractopamin phase shared-us antibioticsoth product apoquel dermat dog expand acut use cytopoint canin atop dermat inject total compani target pharma rimadyl abbott ah sileo nexvet mab pharma undisclos pipelin product could boost diagnost genet test iv fluid embrexoth product assum small bolt-on acquisitionscontract product suppli agreementstot fx boost cowen
compani data cowen compani
compani data cowen compani
state livestock revenu livestock lc ex companion companion lc ex lc ex revenu contract ww lc ex total total dog cowen
compani data cowen compani
valuat methodolog primarili base current year forward price-to-earnings multipl
also consid total return/p ratio discount cash flow
competit dynam global potenti regulatori delay reject failur
and/or polit uncertainti emerg market chang tax law outlook
dividend fluctuat foreign exchang rate
risk price includ abil re-suppli apoquel success pipelin
product weather/diseas risk busi success independ compani
